Table 2.

Three-year RFS rates in relation to histologic marker grade, disease stage, and prognostic accuracy^a

Marker grade	Total (N=851)					Stage II (N=350)			Stage III (N=305)
	RFS	P	HR (95% CI)	CPE	AIC	RFS	P	HR (95% CI)	RFS	P	HR (95% CI)
PDCs		<0.001		0.642	1266		<0.001			<0.001
G1	94.1		Reference			94.0		Reference	89.0		Reference
G2	79.8		3.15 (1.90–5.24)			83.7		2.30 (0.96–5.5)	73.7		2.57 (1.28–5.16)
G3	63.7		6.39 (4.11–9.95)			67.3		4.15 (1.96–8.82)	59.4		4.50 (2.41–8.41)
TB		<0.001		0.629	1281		0.001			<0.001
G1	93.5		Reference			94.0		Reference	86.6		Reference
G2	75.5		3.52 (2.22–5.58)			79.6		2.38 (1.07–5.27)	68.2		2.64 (1.41–4.93)
G3	67.8		4.98 (3.13–7.93)			68.0		3.94 (1.72–9.03)	67.1		2.98 (1.61–5.52)
DRb		<0.001		0.604	1139		0.39			<0.001
Mature	89.9		Reference			92.3		Reference	85		Reference
Intermediate	78.8		1.91 (1.20–3.04)			86.1		1.44 (0.70–2.95)	72.3		1.87 (0.98–3.57)
Immature	65.2		3.79 (2.28–6.31)			75.9		1.89 (0.64–5.59)	61.1		3.52 (1.82–6.78)
CLR	0.021		0.556	1326		0.32			0.020
Present	93.3		Reference			93.4		Reference	91.7		Reference
Absent	84.7		1.86 (1.09–3.16)			87.6		1.47 (0.69–3.13)	73.1		2.61 (1.13–6.05)
PN		<0.001		0.607	1295		0.002			0.003
Absent	92.3		Reference			94.5		Reference	83.1		Reference
Intramural	76.7		2.63 (1.69–4.07)			75.4		3.12 (1.55–6.29)	72.1		1.67 (0.93–3.01)
Extramural	67.6		4.60 (2.82–7.52)			76.5		3.10 (1.05–9.18)	64.2		2.69 (1.49–4.85)
WHO gradec		0.26		0.526	1332					0.37
1	94.4		0.90 (0.22–3.66)
2	87.3		Reference						77.7		Reference
3	83.6		1.47 (0.92–2.36)						73.8		1.28 (075–2.16)

^aP values were calculated using the log-rank test. HR, hazard ratio. Analysis for Stage I was not conducted because the number of events (n=5) was too small.

^bApplicable for T3/4 tumors only (total N=616, stage II N=350, stage III N=266).

^cNot analyzed for stage II due to low numbers of events in some strata.